No foolin': embecta is officially a separate company as of April 1.

The separation is consistent with the Franklin Lakes-based company's growth strategy, allowing it to focus on core innovation priorities.

The medical technology company is formally introducing "embecta," expected to close in the second quarter of 2022, a name with ties to its past, patients and the future.

The standalone company is expected to leverage the Franklin Lakes-based medical technology organization's position as a global leader in insulin delivery, and expand its presence in the sector's large and high-growth market.